Efficacy and predictive factors of transarterial chemoembolization combined with lenvatinib plus programmed cell death protein-1 inhibition for unresectable hepatocellular carcinoma

Table 3 Multivariate Cox regression analysis of overall survival

Variables	Univariate analysis		Multivariate analysis
	HR (95%CI)	P value	HR (95%CI)	P value
Age (≤ 58 yr vs > 58 yr)	0.65 (0.29-1.48)	0.2900
Gender (male vs female)	0.40 (0.11-1.38)	0.0412
ECOG PS (0 vs 1)	0.44 (0.20-0.98)	0.0392
Etiology (HBV vs others)	0.61 (0.21-1.78)	0.2843
BCLC stage (C vs B)	3.11 (1.36-7.11)	0.0068	3.10 (1.18-8.13)	0.021
Maximum tumor diameter (≤ 6.8 vs > 6.8)	0.66 (0.29-1.49)	0.3100
Number of tumors (≤ 3 vs > 3)	0.67 (0.26-1.40)	0.2131
Portal vein invasion (absent vs presence)	0.56 (0.22-1.41)	0.1545
Extrahepatic metastasis (absent vs presence)	0.69 (0.30-1.59)	0.3531
Child-Pugh class (A vs B)	1.29 (0.35-4.78)	0.7266
Baseline AFP (≤ 400 vs > 400)	0.90 (0.39-2.03)	0.7799
Baseline DCP (≤ 40 vs > 40)	1.78 (0.47-6.67)	0.2890
NLR (≤ 3 vs > 3)	0.42 (0.16-1.09)	0.0306
LDH (≤ 198.52 vs > 198.52)	0.43 (0.17-1.06)	0.0347	0.22 (0.08-0.56)	0.002
Early NLR response (decrease vs increase)	0.37 (0.16-0.89)	0.0100	0.31 (0.11-0.89)	0.030
Early AFP response (decrease ≤ 20% vs > 20%)	3.11 (1.31-7.39)	0.0043	3.90 (1.42-10.69)	0.008
Early DCP response (decrease ≤ 20% vs > 20%)	2.42 (0.78-7.51)	0.0407

AFP: Alpha fetoprotein; BCLC: Barcelona Clinic Liver Cancer Classification; DCP: Des-gamma-carboxyprothrombin; ECOG-PS: Eastern Cooperative Oncology Group Performance Status; HBV: Hepatitis B virus; HR: Hazard ratio; LDH: Lactate dehydrogenase; NLR: Neutrophil lymphocyte ratio; PD-1: Programmed cell death protein-1.